TNBC, TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TNBC, TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TNBC, TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to reignite immune attack on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests whether adding radiation and a drug called axatilimab to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer (TNBC) who have already tried immunotherapy. About 34 adults with at least two measurable tumor…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New combo therapy targets hard-to-treat breast cancer
Disease control Not yet recruitingThis study tests whether combining two drugs (Sacituzumab Tirumotecan and Toripalimab) can shrink or control advanced triple-negative breast cancer that has a specific protein (PD-L1). About 41 women with this type of breast cancer will receive the treatment. The goal is to see h…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
Gut bacteria boosts breast cancer treatment? new trial launches
Disease control Not yet recruitingThis phase 2 trial tests whether adding a live bacteria supplement (MO-03) to standard chemotherapy and immunotherapy (pembrolizumab) can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants take the supplement twice daily until surgery, the…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New targeted drug takes on hard-to-treat breast cancers
Disease control Not yet recruitingThis study tests a new drug called SC-101 in people with advanced breast cancer that has a specific gene change (NECTIN4). The goal is to see if the drug can shrink tumors and how safe it is. About 120 adults aged 18 to 75 with triple-negative or hormone-receptor-positive breast …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could a lighter chemo combo work for some breast cancer patients?
Disease control Not yet recruitingThis study tests a less intense treatment for people with early-stage triple-negative breast cancer. It combines two drugs, sacituzumab govitecan and tislelizumab, to see if they can shrink tumors before surgery. The goal is to find out which patients can safely use this milder a…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Immunotherapy plus chemo shows promise in tough breast cancer
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy combinations. The mai…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New pill aims to keep advanced breast cancer in check after chemo
Disease control Not yet recruitingThis study tests a daily pill called fluzoparib for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The goal is to see if fluzoparib can delay cancer growth as a maintenance treatment. About 72 participants with or without…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New hope for hard-to-treat breast cancer? drug duo targets PIK3CA mutation
Disease control Not yet recruitingThis study tests a combination of two drugs (inavolisib and eribulin) in people with advanced triple-negative breast cancer that has a specific genetic change called PIK3CA mutation. The goal is to see if the combo can shrink tumors. About 26 participants who have already tried a…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New study aims to improve Pre-Surgery treatment for aggressive breast cancer
Knowledge-focused Not yet recruitingThis study looks back at medical records of 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to see which treatment leads to a complete disappearance of cancer in the breast and lymph nodes, and what factors affe…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated May 11, 2026 20:49 UTC